Last reviewed · How we verify

Salbutamol (200 µg) — Competitive Intelligence Brief

Salbutamol (200 µg) (Salbutamol (200 µg)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: β2 adrenergic receptor agonist. Area: Respiratory.

phase 3 β2 adrenergic receptor agonist β2 adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Salbutamol (200 µg) (Salbutamol (200 µg)) — Novartis. Salbutamol is a short-acting β2 adrenergic receptor agonist that works by stimulating the β2 receptors in the lungs, causing bronchodilation and relaxation of bronchial smooth muscle.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Salbutamol (200 µg) TARGET Salbutamol (200 µg) Novartis phase 3 β2 adrenergic receptor agonist β2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (β2 adrenergic receptor agonist class)

  1. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salbutamol (200 µg) — Competitive Intelligence Brief. https://druglandscape.com/ci/salbutamol-200-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: